RxDoctor Payments Data

Barbara Epps

Family · Sumter, SCNPI 1700391430

Payments from drug & device makers

$1,147in general payments, 2019–2025

Across 75 payments — averaging $15.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$386
  • Novo Nordisk$106
  • Astellas Pharma US Inc$85
  • Otsuka America Pharmaceutical, Inc.$68
  • Biohaven Pharmaceutical Holding Company Ltd.$67
  • Merck$53
  • plus $383 from 15 others

What the payments were for

  • Food & beverage$1,06293%
  • Education$857%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,147 in reported general payments places this provider in the 65th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$182,092
Medicare patients
244
Services billed
3,285

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide58$77,715
JardianceEmpagliflozin24$34,343
TrulicityDulaglutide26$33,408
LinzessLinaclotide33$27,719
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$24,584
OzempicSemaglutide20$23,449
EntrestoSacubitril/Valsartan18$18,085
XareltoRivaroxaban20$15,663
Synjardy XrEmpagliflozin/Metformin Hcl13$11,709
GemtesaVibegron13$7,840
Repatha SureclickEvolocumab12$6,392
EliquisApixaban11$5,993
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog30$3,302
Lantus SolostarInsulin Glargine,hum.Rec.Anlog42$3,083
Tolterodine Tartrate ErTolterodine Tartrate18$2,233

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$48$111,12384 claims
Boehringer IngelheimJardiance, Synjardy Xr$29$46,05237 claims
AbbVieLinzess$386$27,71933 claims
Novo NordiskOzempic$106$23,44920 claims
NovartisEntresto$19$18,08518 claims
Sumitomo Pharma America, Inc.Gemtesa$35$7,84013 claims
PfizerEliquis$11$5,99311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,248 family providers in South Carolina.

Other family in Sumter

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →